All In Biotech

Drug Trial Radar · NCT07526974

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Aug 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.

Conditions

  • Subcutaneous Fat

Interventions

  • CBL-514 InjectionDrug

    Provided as a ready for use injectable CBL-514 solution

  • 0.9% Sodium ChlorideDrug

    Injectable 0.9% Sodium Chloride solution as placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving at least a 2-grade improvement on Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.Time frame: From baseline to 4 weeks after final treatment

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site 1

    Encinitas, California · Not yet recruiting

  • Investigational site 2

    Aventura, Florida · Not yet recruiting

  • Investigational site 15

    Miami, Florida · Recruiting

  • Investigational Site 3

    Alpharetta, Georgia · Not yet recruiting

  • Investigational site 16

    Baton Rouge, Louisiana · Recruiting

  • Investigational Site 4

    Hunt Valley, Maryland · Not yet recruiting

  • Investigational site 5

    Omaha, Nebraska · Not yet recruiting

  • Investigational site 6

    New York, New York · Not yet recruiting

  • Investigational Site 7

    Canal Winchester, Ohio · Not yet recruiting

  • Investigational site 8

    Nashville, Tennessee · Not yet recruiting

  • Investigational site 9

    Austin, Texas · Not yet recruiting

  • Investigational Site 10

    Arlington, Virginia · Not yet recruiting

  • Investigational Site 11

    Seattle, Washington · Not yet recruiting

  • Investigational Site 13

    Vancouver, British Columbia, Canada · Not yet recruiting

  • Investigational Site 14

    Woodbridge, Ontario, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.